Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.

Products

Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products

Our pipeline

Sobi’s pipeline programs are focused on recombinant protein drugs for specialist indications for the global market.
Read more about Sobi's pipeline

Annual General Meeting

Sobi’s AGM was held on Friday, April 26, 2013, at Kungliga Ingenjörsvetenskapsakademien (IVA), Stockholm, Sweden.
Read more

Presentation of Sobi's first quarter results, 2013

April 26, 2013 - Revenues for the quarter totalled MSEK 528.5 (506.7), with continued momentum across the commercial portfolio and several significant advances in the pipeline.

Share Price

SEK41.80

Volume: 242149
Ticker: SOBI
List:
SSE Mid Cap